ALEC ALECTOR

Alector to Participate in Upcoming Healthcare Conferences

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

  • Bank of America Securities Health Care Conference (Las Vegas, Nevada)
    • Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation
  • H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, New York)
    • Tuesday, May 20, 2025, at 12:00 p.m. ET, fireside chat

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at . Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector

Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit .

Alector Contacts:

Alector

Katie Hogan

202-549-0557

Argot Partners (media)

David Rosen

646-461-6387

Argot Partners (investors)

Laura Perry

212-600-1902



EN
06/05/2025

Underlying

ALECALECTOR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALECTOR

 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in the TD Cowen 46th Annual Health Care Confere...

Alector to Participate in the TD Cowen 46th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET. A live webcast of the corporate presentation will be available on the “Events & Presentations” page within the Investors s...

February 24, 2026 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Bus...

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector’s Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. “Neil has...

December 12, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in the Bank of America CNS Therapeutics Confere...

Alector to Participate in the Bank of America CNS Therapeutics Conference SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference, being held virtually on Monday, December 8, 2025, at 2:25 pm ET. A webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors ...

December 1, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Reports Third Quarter 2025 Financial Results and Provides Busi...

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson’s disease; both advancing toward IND-enabling studies Advancing ABC-enabled Tau, Alpha Synuclein and NLRP3 siRNA programs targeting peripheral delivery of novel therapies for neurodegenerative disorders Independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101) in ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Announces Topline Results from Latozinemab Phase 3 Trial in In...

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). In the 96-week, dou...

October 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch